+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Studies on the usefulness of a long term high dose treatment of methylcobalamin for patients with oligozoospermia

Studies on the usefulness of a long term high dose treatment of methylcobalamin for patients with oligozoospermia

Acta Urologica Japonica 33(1): 151-156

Methylcobalamin (CH3-B12) was administered in a dose of 6 mg per day (group A, 16 cases) or 12 mg per day (group B, 23 cases) for 16 weeks to patients with oligozoospermia. There was no difference between group A and group B regarding vitamin B12 concentrations in the serum or seminal fluid. CH3-B12 appeared to be transported to seminal fluid very efficiently. However, results from group A and group B did not differ from respect to this parameter. The efficacy rate for group A was 37.5% and that for group B was 39.1%. From these results, it was concluded that a long-term, high dose treatment of CH3-B12 was useful for the treatment of patients with oligozoospermia. Since the efficacy rates were not different between the two groups, 6 mg per day would be the recommended dose. Clinical adverse in one patient in each group. Drug-related laboratory adverse reactions were observed in only one patient in group B.

(PDF 0-2 workdays service: $29.90)

Accession: 006522846

Download citation: RISBibTeXText

Related references

Studies on the usefulness of a long-term, high-dose treatment of methylcobalamin in patients with oligozoospermia. Hinyokika Kiyo. Acta Urologica Japonica 33(1): 151-156, 1987

High-dose inhaled beclomethasone in long-term management of chronic severe asthma--usefulness and dose-dependence. Nihon Kyobu Shikkan Gakkai Zasshi 34(5): 536-544, 1996

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 119(13): 3184-3185, 2012

A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. Experimental Hematology 35(7): 1074-1082, 2007

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: Long term results for 105 patients. Cancer 85(7): 1555-1564, April 1, 1999

Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. American Journal of Cardiology 95(2): 264-266, 2005

Long-term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: a single-center experience. ChemoTherapy 60(4): 228-238, 2015

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. Journal of Clinical Endocrinology and Metabolism 75(5): 1310-1317, 1992

Long term cytogenetic studies of 10 patients with hyperthyroidism after single dose treatment with radioiodine. Mutation Research 147(5): 316, 1985

Long term pulsatile low dose subcutaneous lhrh administration in men with idiopathic oligozoospermia failure of therapeutic and hormonal response. Andrologia 17(2): 143-149, 1985

Result of long-term Methylcobalamin treatment for male infertility. Japanese Journal of Fertility & Sterility 48(3-4): 119-124, October, 2003

Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Alimentary Pharmacology & Therapeutics 8 Suppl 1: 59-64, 1994

Long-term follow-up of low-grade lymphoma patients receiving high-dose chemotherapy with autograft as primary treatment. Blood 94(10 SUPPL 1 PART 2): 406b, Nov 15, 1999

Long term treatment of oligozoospermia using the aromatase inhibitor testolactone. Hautarzt 38(7): 395-399, 1987